Bridging the gap in protein targeting

Irene Serrano

DOI: https://doi.org/10.1038/s41589-024-01766-3

IF: 14.8

2024-10-22

Nature Chemical Biology

Abstract:Targeted protein degradation has emerged as a highly promising therapeutic approach to modulate proteins that are difficult to target with conventional small molecules. This approach has recently been expanded to include alteration of extracellular protein levels and activity — including both secreted and membrane proteins. Now, Zhang et al. have exploited the upregulation of cell surface transferrin receptor 1 (TfR1) in cancer cells and its rapid endocytosis rate to develop transferrin receptor targeting chimeras (TransTACs). These are heterobispecific antibodies that induce internalization and lysosomal degradation of target membrane proteins. The team investigated the capacity of TransTACs to eliminate surface chimeric antigen receptor (CAR). Despite undergoing internalization, CAR is not subjected to degradation; instead, it is trafficked to the recycling endosomes. To address this the team incorporated an antibody binder to TfR1 and a cathepsin B cleavage linker to facilitate CAR entry into the lysosomal degradation pathway. CAR TransTACs can effectively inhibit the activation of Jurkat and human primary CAR T cells, as well as secretion of IFNγ. Furthermore, the target scope was expanded to include epidermal growth factor receptor (EGFR) for targeting drug-resistant lung cancer, as well as PD-L1 and CD20, demonstrating the capacity of TransTACs to efficiently internalize and degrade structurally and functionally distinct membrane proteins.

biochemistry & molecular biology